BIO 2015 Dispatches: Asset Swaps Won't Replace Mega-mergers
This article was originally published in The Pink Sheet Daily
Business development executives from AstraZeneca, Novartis and Almirall discussed the benefits of assets swaps and if they think mega-mergers are an outdated trend.
You may also be interested in...
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.